1 |
Atmar J. Review of the safety and feasibility of rapid infusion of rituximab. Journal of oncology practice. American Society of Clinical Oncology 2010; 6(2): 91-3.
|
2 |
Davis TA, Grillo-Lopez AJ, White CA, et al., Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. Journal of clinical oncology 2000; 18(17): 3135-43.
|
3 |
Maloney DG, Grillo-Lopez AJ, White CA, et al., IDECC2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90(6): 2188-95.
|
4 |
Maloney DG, Liles TM, Czerwinski DK, et al., Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84(8): 2457-66.
|
5 |
Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al., IDECC2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. Journal of clinical oncology 1997; 15(10): 3266-74.
|
6 |
McLaughlin P, Grillo-Lopez AJ, Link BK, et al., Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of clinical oncology 1998; 16(8): 2825-33.
|
7 |
Piro LD, White CA, Grillo-Lopez AJ, et al., Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non- Hodgkin's lymphoma. Annals of oncology 1999; 10(6): 655-61.
DOI
|
8 |
Dillman RO, Hendrix CS. Unique aspects of supportive care using monoclonal antibodies in cancer treatment. Supportive cancer therapy 2003; 1(1): 38-48.
DOI
|
9 |
Breslin S. Cytokine-release syndrome: overview and nursing implications. Clinical journal of oncology nursing 2007; 11(1 Suppl): 37-42.
DOI
|
10 |
Lang DS, Keefe DM, Schultz T, et al., Predictors of acute adverse events from rapid rituximab infusion. Supportive care in cancer 2013; Epub ahead of print.
|
11 |
Hong J, Kim JY, Ahn HK, et al., Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma. Supportive care in cancer 2013; 21(4): 1145-52.
DOI
|
12 |
Byrd JC, Waselenko JK, Maneatis TJ, et al., Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. Journal of clinical oncology 1999; 17(3): 791-5.
|
13 |
Winkler U, Jensen M, Manzke O, et al., Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDECC2B8). Blood 1999; 94(7): 2217-24.
|
14 |
Roche (2012) Mabthera, Roche Products Pty Limited [updated 21 April 2012]; Available from : http://www.roche. co.kr/fmfiles/re7198001/product/insertpaper/Mabthera_inj.pdf. Last accessed on 22 April 2013.
|
15 |
Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63(8): 803-43.
DOI
|
16 |
Coiffier B, Lepage E, Briere J, et al., CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. NEJM 2002; 346(4): 235-42.
DOI
|
17 |
Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. The NEJM 2008; 359(6): 613-26.
DOI
|
18 |
Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer metastasis reviews 1999; 18(4): 465-71.
DOI
|
19 |
Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. The oncologist 2007; 12(5): 601-9.
DOI
|
20 |
Institute NC. Common Terminology Criteria for Adverse Events(CTACE) v4.03. 2010.
|
21 |
Kimby E. Tolerability and safety of rituximab (MabThera). Cancer treatment reviews 2005; 31(6): 456-73.
DOI
|
22 |
Kang SP, Saif MW. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. The journal of supportive oncology 2007; 5(9): 451-7.
|
23 |
Czuczman MS, Grillo-Lopez AJ, White CA, et al., Treatment of patients with low-grade B-cell lymphoma with the combination of chimaeric anti CD-20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-76.
|
24 |
Tuthill M, Crook T, Corbet T, et al., Rapid infusion of rituximab over 60 min. Eur J Haematol 2009; 82(4): 322-5.
DOI
|
25 |
Al Zahrani A, Ibrahim N, Al Eid A. Rapid infusion rituximab changing practice for patient care. J Oncol Pharm Pract 2009; 15(3): 183-6.
DOI
|